MBX Biosciences, Inc. Common Stock Asset Resilience Ratio
MBX Biosciences, Inc. Common Stock asset resilience ratio. MBX Biosciences, Inc. Common Stock (MBX) has an Asset Resilience Ratio of 87.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MBX Biosciences, Inc. Common Stock (MBX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MBX Biosciences, Inc. Common Stock (2022–2025)
Asset resilience ratio of MBX Biosciences, Inc. Common Stock from 2022 to 2025. This chart shows how MBX Biosciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read debt load of MBX Biosciences, Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MBX Biosciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of MBX Biosciences, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $394.76 Million | 87.2% |
| Total Liquid Assets | $394.76 Million | 87.20% |
Asset Resilience Insights
- Very High Liquidity: MBX Biosciences, Inc. Common Stock maintains exceptional liquid asset reserves at 87.20% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MBX Biosciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MBX Biosciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
MBX Biosciences, Inc. Common Stock Asset Resilience Ratio by Year (2022–2025)
MBX Biosciences, Inc. Common Stock asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for MBX Biosciences, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 77.48% | $298.42 Million | $385.14 Million | -1.76pp |
| 2024-12-31 | 79.24% | $212.80 Million | $268.54 Million | +19.67pp |
| 2023-12-31 | 59.58% | $50.15 Million | $84.18 Million | +19.11pp |
| 2022-12-31 | 40.47% | $18.25 Million | $45.09 Million | -- |
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also devel… Read more